What You Should Know:
– Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN), a clinical-stage biotechnology company focused on developing organ regeneration technology for severe diseases, has secured approximately $5 million from a new investor through a private placement of shares.
– The funds will be allocated to expedite the clinical development of HRGN’s lead product candidate, the HRGN Esophageal Implant (BEI).
– The FDA has approved a phase one and phase two clinical trial involving ten adult patients to study the repair of esophageal damage caused by cancer or injury.
– Upon demonstrating safety in adults, the FDA may consider expanding the trial to include pediatric subjects with esophageal birth defects, a potential new indication for which HRGN plans to seek FDA approval.
